MedPath

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Phase 2
Completed
Conditions
Type II Diabetes Mellitus
Interventions
Drug: JTT-130 Placebo
Registration Number
NCT00929539
Lead Sponsor
Akros Pharma Inc.
Brief Summary

The purpose of this study is to evaluate the effect of JTT-130 on diabetes as well as the safety and tolerability of JTT-130 in obese Type 2 diabetic patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
496
Inclusion Criteria
  1. Have type 2 diabetes;
  2. Body mass index (BMI) of > 27.0 kg/m2 and ≤ 45.0 kg/m2;
  3. Are either drug naïve with respect to hypoglycemic agents OR are currently being treated with metformin alone or in combination with a sulfonylurea. Metformin and sulfonylurea dosing must be stable.
Exclusion Criteria
  1. Females who are pregnant or breast-feeding
  2. Known medical history or presence of type 1 diabetes, pancreatitis, unstable or rapidly progressing retinopathy, nephropathy or neuropathy;
  3. Acute coronary syndrome or uncontrolled hypertension;
  4. Does not meet medication restriction criteria, as described in the protocol.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Dose 1 JTT-130JTT-130-
PlaceboJTT-130 Placebo-
Dose 2 JTT-130JTT-130-
Dose 3 JTT-130JTT-130-
Primary Outcome Measures
NameTimeMethod
Change in glycosylated hemoglobin (HbA1c) levelsEnd of Study
Secondary Outcome Measures
NameTimeMethod
Safety and tolerability dataEnd of Study
© Copyright 2025. All Rights Reserved by MedPath